|
|
Article: Inverness Medical Innovations' Subsidiary Wampole Laboratories Announces Agreement with Roche Diagnostics for Cardiac Test.
- Article from:
- PR Newswire
- Article date:
- July 11, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WALTHAM, Mass., July 11 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. announced today that its subsidiary Wampole Laboratories has signed an agreement with Roche Diagnostics to collaborate on the first fully automated diagnostic test for Ischemia Modified Albumin (IMA(R)). The current plan is for the Albumin Cobalt Binding (ACB(R)) test for detection of IMA(R) to be available on the Roche Cobas Integra(R) 700 and Cobas Integra(R) 800 chemistry analyzer systems, and Inverness is currently preparing to submit a pre-market notification with the FDA for clearance. IMA(R) is a key marker of cardiac ischemia used in the assessment of patients with chest pain ...
Related newspaper, magazine, and journal articles:
|
|
Article: Frost & Sullivan Names Roche Diagnostics Clinical ...
PR Newswire;
November 17, 2004 ;
700+ words
... ... and intelligence firm, presented Roche Diagnostics Corporation with the Clinical Diagnostics ... Life Sciences Awards Banquet. "Roche Diagnostics' innovation and effective cultivation ... to its customers that has helped Roche Diagnostics maintain solid growth," said Manoj ...
|
|